Pfizer and Moderna say children as young as 5 could be eligible for COVID vaccines by early September, as both companies complete trials.
Pfizer said Tuesday it is advancing late-stage clinical trials of its COVID vaccine, in lower doses, on children ages 5 to 11 years old and expects to apply for approval early this fall.
Pfizer’s vaccine is already being administered to children 12 and up, who receive the same 30 microgram dose as adults.
Moderna said it also expects its COVID vaccine will be available for kids as young as 5 by early fall. CEO Stéphane Bancel said Monday he thinks the data will become available sometime in September, CBS Boston reported.
Earlier this month, Moderna applied to the U.S. Food and Drug Administration (FDA) for full approval of its COVID vaccine for adults 18 and older, which is being administered now under Emergency Use Authorization. The company said it plans to seek expanded emergency use approval in the U.S. for the vaccine for ages 12 and up early this month.
Pfizer plans trials on children as young as 6 months
The Pfizer study on children 5 to 11 will enroll up to 4,500 children at more than 90 clinical sites in the U.S., Finland, Poland and Spain, the company said.
Based on safety, efficacy and tolerability data from the 144 children included in Pfizer’s phase 1 trial, the company will use 10 micrograms of each vaccine dose for kids between the ages of 5 and 11 in phase 2/3 trials, and 3 micrograms of each dose for those 5 and younger.